이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ekso Bionics Holdings 배당금

배당금 기준 확인 0/6

Ekso Bionics Holdings 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.78
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Jun 04

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

May 26

What Is The Ownership Structure Like For Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

Feb 10

Ekso Bionics sees lower 2020 sales vs. 2019

Jan 13

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Dec 23

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 EKSO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: EKSO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Ekso Bionics Holdings 시장 대비 배당 수익률

EKSO 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (EKSO)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Medical Equipment)	1.8%
3년 후 애널리스트 예측 (EKSO)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 EKSO 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 EKSO 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 EKSO 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: EKSO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Ekso Bionics Holdings 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 12%, EPS downgraded

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Executive Chairman of the Board recently sold US$66k worth of stock

Consensus EPS estimates fall by 40%

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Price target decreased to US$9.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ekso Bionics: Fragile Opportunity

Second quarter 2022 earnings: EPS exceeds analyst expectations

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Ekso Bionics: Expecting More Of The Same

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

Ekso Bionics: Have Robot, Might Travel

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Director has left the company

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021

Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Ekso Bionics Holdings, Inc. to Report Q4, 2020 Results on Feb 25, 2021

What Is The Ownership Structure Like For Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

Ekso Bionics Holdings, Inc. Announces Resignation of Ted Wang as Member of the Board of Director

New 90-day high: US$13.07

Ekso Bionics sees lower 2020 sales vs. 2019